Takahito Fukusumi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Takahito Fukusumi has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Akihiro Sakai
Department of Otolaryngology, Head and Neck Surgery Tokai University, School of Medicine Isehara Japan
20 shared publications - Jorge Silvio Gutkind
University of California San Diego 5 La Jolla, California
20 shared publications - Joseph A. Califano
Affiliations Moores Cancer Center, UC San Diego, La Jolla, California United States of America, Department of Otolaryngology-Head and Neck Surgery, UC San Diego School of Medicine, San Diego, California, United States of America, Gleiberman Head and Neck Cancer Center, UC San Diego, La Jolla, California, United States of America
20 shared publications - Mizuo Ando
Department of Otolaryngology-Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
20 shared publications - Panomwat Amornphimoltham
Oral and Pharyngeal Cancer Branch, National Institute of Craniofacial and Dental Research, NIH, Bethesda, Maryland and
20 shared publications - Shuling Ren
Moores Cancer Center, University of California San Diego, La Jolla, CA, USA
20 shared publications
Latest Publications
- Open Access
- 9 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (20) , 7772
Longitudinal Voice Outcomes After Atelocollagen Injection Laryngoplasty for Vocal Fold Paralysis and Vocal Fold Atrophy/Sulcus
Background: Atelocollagen injection laryngoplasty is a minimally invasive treatment for glottic insufficiency, but the durability of its effects and whether longitudinal responses differ according to the underlying disorder remain unclear. Methods: We retrospectively analyzed prospectively collected clinical data from three institutions. The cohort comprised 92 patients and 142 injection episodes, including 75 patients with vocal fold paralysis and 17 with vocal fold atrophy/sulcus. Acoustic Voice Quality Index (AVQI), maximum phonation time (MPT), and Voice Handicap Index-10 (VHI-10) were evaluated from baseline through 1 year. Longitudinal changes were analyzed using mixed-effects models, and clinically meaningful response was assessed using prespecified criteria. Extended follow-up at 1.5 years and ≥2 years was evaluated in the subset of patients with vocal fold paralysis with available long-term data. Results: In vocal fold paralysis, AVQI, MPT, and VHI-10 improved significantly at all follow-up time points through 1 year. In vocal fold atrophy/sulcus, AVQI and VHI-10 showed significant improvement mainly at 1 and 3 months, whereas MPT did not show consistent improvement. The time-by-disease-group interaction was significant for AVQI (p = 0.006), but not for MPT (p = 0.239) or VHI-10 (p = 0.559). AVQI responder trajectories also differed between disease groups (p = 0.023). In the available long-term subset (n = 19 at each time point), all three outcomes remained significantly improved at 1.5 years and ≥2 years. At ≥2 years, responder rates were 41.9% for AVQI and 48.4% for VHI-10, and MPT functional recovery was 31.6%. Conclusions: Atelocollagen injection laryngoplasty was associated with sustained voice improvement through 1 year in vocal fold paralysis, with improvement also observed at ≥2 years in a selected subset. Effects in vocal fold atrophy/sulcus were less consistently sustained.
- 9 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (20) , 7772
Open AccessLongitudinal Voice Outcomes After Atelocollagen Injection Laryngoplasty for Vocal Fold Paralysis and Vocal Fold Atrophy/Sulcus
Background: Atelocollagen injection laryngoplasty is a minimally invasive treatment for glottic insufficiency, but the durability of its effects and whether longitudinal responses differ according to the underlying disorder remain unclear. Methods: We retrospectively analyzed prospectively collected clinical data from three institutions. The cohort comprised 92 patients and 142 injection episodes, including 75 patients with vocal fold paralysis and 17 with vocal fold atrophy/sulcus. Acoustic Voice Quality Index (AVQI), maximum phonation time (MPT), and Voice Handicap Index-10 (VHI-10) were evaluated from baseline through 1 year. Longitudinal changes were analyzed using mixed-effects models, and clinically meaningful response was assessed using prespecified criteria. Extended follow-up at 1.5 years and ≥2 years was evaluated in the subset of patients with vocal fold paralysis with available long-term data. Results: In vocal fold paralysis, AVQI, MPT, and VHI-10 improved significantly at all follow-up time points through 1 year. In vocal fold atrophy/sulcus, AVQI and VHI-10 showed significant improvement mainly at 1 and 3 months, whereas MPT did not show consistent improvement. The time-by-disease-group interaction was significant for AVQI (p = 0.006), but not for MPT (p = 0.239) or VHI-10 (p = 0.559). AVQI responder trajectories also differed between disease groups (p = 0.023). In the available long-term subset (n = 19 at each time point), all three outcomes remained significantly improved at 1.5 years and ≥2 years. At ≥2 years, responder rates were 41.9% for AVQI and 48.4% for VHI-10, and MPT functional recovery was 31.6%. Conclusions: Atelocollagen injection laryngoplasty was associated with sustained voice improvement through 1 year in vocal fold paralysis, with improvement also observed at ≥2 years in a selected subset. Effects in vocal fold atrophy/sulcus were less consistently sustained.
- Open Access
- 26 January 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-22
Intratumor heterogeneity of HPV integration in HPV-associated head and neck cancer
Integration of human papillomavirus (HPV) into the host genome drives HPV-positive head and neck squamous cell carcinoma (HPV+ HNSCC). Whole-genome sequencing of 51 tumors revealed intratumor heterogeneity of HPV integration, with 44% of breakpoints subclonal, and a biased distribution of integration breakpoints across the HPV genome. Four HPV physical states were identified, with at least 49% of tumors progressing without integration. HPV integration was associated with APOBEC-induced broad genomic instability and focal genomic instability, including structural variants at integration sites. HPV+ HNSCCs exhibited almost no smoking-induced mutational signatures. Heterozygous loss of ataxia-telangiectasia mutated (ATM) was observed in 67% of tumors, with its downregulation confirmed by single-cell RNA sequencing and immunohistochemistry, suggesting ATM haploinsufficiency contributes to carcinogenesis. PI3K activation was the major oncogenic mutation, with JAK-STAT activation in tumors with clonal integration and NF-kappa B activation in those without. These findings provide valuable insights into HPV integration in HPV+ HNSCC.
- 26 January 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-22
Open AccessIntratumor heterogeneity of HPV integration in HPV-associated head and neck cancer
Integration of human papillomavirus (HPV) into the host genome drives HPV-positive head and neck squamous cell carcinoma (HPV+ HNSCC). Whole-genome sequencing of 51 tumors revealed intratumor heterogeneity of HPV integration, with 44% of breakpoints subclonal, and a biased distribution of integration breakpoints across the HPV genome. Four HPV physical states were identified, with at least 49% of tumors progressing without integration. HPV integration was associated with APOBEC-induced broad genomic instability and focal genomic instability, including structural variants at integration sites. HPV+ HNSCCs exhibited almost no smoking-induced mutational signatures. Heterozygous loss of ataxia-telangiectasia mutated (ATM) was observed in 67% of tumors, with its downregulation confirmed by single-cell RNA sequencing and immunohistochemistry, suggesting ATM haploinsufficiency contributes to carcinogenesis. PI3K activation was the major oncogenic mutation, with JAK-STAT activation in tumors with clonal integration and NF-kappa B activation in those without. These findings provide valuable insights into HPV integration in HPV+ HNSCC.
- Open Access
- 15 September 2023
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 29 (18_Supplem) , PO-026-026
Abstract PO-026: Intra-tumor heterogeneity of HPV integration and its association with focal genomic instability in oropharyngeal cancer
Human papillomavirus (HPV) integration has been considered as one of the driver factors for cancer progression, but its pattern and role in carcinogenesis is still unclear. Whole genome sequencing data of 14 Japanese HPV16+ OPSCC and 13 HPV+ OPSCC from Pan-Cancer Analysis of Whole Genomes were used to identify integrations and somatic mutations. The phylogenetic analysis of HPV16 revealed that in tumors of 14 Japanese subjects, the A4 variant was the most common (8/14, 57.1%), followed by the A5 variant (2/14, 14.3%), which is considered unique to HPV16 in East and Southeast Asian, and the A2/A3/D2/D3 variants (1/14, 7.1%), showing a significant difference from the distribution of the HPV16 sublineages in Europe and the United States, where the A1 variant accounts for half. A total of 250 integration breakpoints (BPs) in 20 of the 27 tumors (74.1%) were detected. We estimated the cancer cell fraction of integration BPs and found that HPV integration also shows intra-tumor heterogeneity, indicating that nearly half of the integration events occurred after carcinogenesis. Clonal BPs were more likely to occur in the E1 (P = 0.036), confirming that the disruption of the E1 gene may result in abnormal negative regulation of the E6/E7 oncogenes and promote OPSCC carcinogenesis. Subclonal BPs were less likely to occur in the E6 (P = 0.045), suggesting that the E6 may also play an important role in the process of cancer evolution after carcinogenesis. Four states of the HPV genome were identified: (1) episomal-only (7/27, 25.9%), (2) integrated-only (4/27, 14.8%), (3) clonally-mixed (episomal + clonally integrated) (11/27, 40.7%), and (4) subclonally-mixed (episomal + subclonally integrated) (5/27, 18.5%). Since nearly half of these cancers have developed with just episomal copies of HPV, integration itself is not essential for carcinogenesis and can occur during and after carcinogenesis. Interestingly, the E6/E7 were conserved in all four cancers with integrated-only HPV, while the E2 and E1 were disrupted or deleted. This confirms that the constitutive expression of E6/E7 is essential for the carcinogenesis of HPV+ OPSCC. These results suggest that some integrations may be drivers of carcinogenesis with disruption of E1/E2, as in these four cancers, and others may arise randomly due to genomic instability, as in the cancers with the E6/E7 deleted integrants. The number of BPs of structural variations (SVs) occurred in the overlapping 100 kb regions flanking integration BPs (ITG regions) was positively correlated with the number of integration BPs (Spearman’s rank correlation ρ = 0.78; Permutation test P = 9.9 × 10−5). The genomic instability that causes clonal integrations during carcinogenesis is considered to cause clonal SVs, mainly large duplications, and subclonal integrations and SVs such as large deletions. Clonal SVs, mainly large duplications, were also observed in the regions where only subclonal integrations occurred, suggesting that large duplications occur before integrations. Citation Format: Noah Sasa, Hirotaka Eguchi, Hidenori Tanaka, Takahito Fukusumi, Motoyuki Suzuki, Yukinori Takenaka, Yukinori Okada, Hidenori Inohara. Intra-tumor heterogeneity of HPV integration and its association with focal genomic instability in oropharyngeal cancer [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Innovating through Basic, Clinical, and Translational Research; 2023 Jul 7-8; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2023;29(18_Suppl):Abstract nr PO-026.
- 15 September 2023
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 29 (18_Supplem) , PO-026-026
Open AccessAbstract PO-026: Intra-tumor heterogeneity of HPV integration and its association with focal genomic instability in oropharyngeal cancer
Human papillomavirus (HPV) integration has been considered as one of the driver factors for cancer progression, but its pattern and role in carcinogenesis is still unclear. Whole genome sequencing data of 14 Japanese HPV16+ OPSCC and 13 HPV+ OPSCC from Pan-Cancer Analysis of Whole Genomes were used to identify integrations and somatic mutations. The phylogenetic analysis of HPV16 revealed that in tumors of 14 Japanese subjects, the A4 variant was the most common (8/14, 57.1%), followed by the A5 variant (2/14, 14.3%), which is considered unique to HPV16 in East and Southeast Asian, and the A2/A3/D2/D3 variants (1/14, 7.1%), showing a significant difference from the distribution of the HPV16 sublineages in Europe and the United States, where the A1 variant accounts for half. A total of 250 integration breakpoints (BPs) in 20 of the 27 tumors (74.1%) were detected. We estimated the cancer cell fraction of integration BPs and found that HPV integration also shows intra-tumor heterogeneity, indicating that nearly half of the integration events occurred after carcinogenesis. Clonal BPs were more likely to occur in the E1 (P = 0.036), confirming that the disruption of the E1 gene may result in abnormal negative regulation of the E6/E7 oncogenes and promote OPSCC carcinogenesis. Subclonal BPs were less likely to occur in the E6 (P = 0.045), suggesting that the E6 may also play an important role in the process of cancer evolution after carcinogenesis. Four states of the HPV genome were identified: (1) episomal-only (7/27, 25.9%), (2) integrated-only (4/27, 14.8%), (3) clonally-mixed (episomal + clonally integrated) (11/27, 40.7%), and (4) subclonally-mixed (episomal + subclonally integrated) (5/27, 18.5%). Since nearly half of these cancers have developed with just episomal copies of HPV, integration itself is not essential for carcinogenesis and can occur during and after carcinogenesis. Interestingly, the E6/E7 were conserved in all four cancers with integrated-only HPV, while the E2 and E1 were disrupted or deleted. This confirms that the constitutive expression of E6/E7 is essential for the carcinogenesis of HPV+ OPSCC. These results suggest that some integrations may be drivers of carcinogenesis with disruption of E1/E2, as in these four cancers, and others may arise randomly due to genomic instability, as in the cancers with the E6/E7 deleted integrants. The number of BPs of structural variations (SVs) occurred in the overlapping 100 kb regions flanking integration BPs (ITG regions) was positively correlated with the number of integration BPs (Spearman’s rank correlation ρ = 0.78; Permutation test P = 9.9 × 10−5). The genomic instability that causes clonal integrations during carcinogenesis is considered to cause clonal SVs, mainly large duplications, and subclonal integrations and SVs such as large deletions. Clonal SVs, mainly large duplications, were also observed in the regions where only subclonal integrations occurred, suggesting that large duplications occur before integrations. Citation Format: Noah Sasa, Hirotaka Eguchi, Hidenori Tanaka, Takahito Fukusumi, Motoyuki Suzuki, Yukinori Takenaka, Yukinori Okada, Hidenori Inohara. Intra-tumor heterogeneity of HPV integration and its association with focal genomic instability in oropharyngeal cancer [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Innovating through Basic, Clinical, and Translational Research; 2023 Jul 7-8; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2023;29(18_Suppl):Abstract nr PO-026.
- Open Access
- 15 August 2023
- Published by Elsevier in Advances in Radiation Oncology
- Vol. 9 (2) , 101353
Circulating Plasma Exosomal PD-L1 Predicts Prognosis of Head and Neck Squamous Cell Carcinoma After Radiation Therapy
- 15 August 2023
- Published by Elsevier in Advances in Radiation Oncology
- Vol. 9 (2) , 101353
Open AccessCirculating Plasma Exosomal PD-L1 Predicts Prognosis of Head and Neck Squamous Cell Carcinoma After Radiation Therapy
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S3 from The NOTCH4–HEY1 Pathway Induces Epithelial–Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma
Figure S3. Sphere colony shapes. HEY1 expression in si-HEY1 cells and NOTCH4 expressions in sh-NOTCH4 cells
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from The NOTCH4–HEY1 Pathway Induces Epithelial–Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma
Figure S3. Sphere colony shapes. HEY1 expression in si-HEY1 cells and NOTCH4 expressions in sh-NOTCH4 cells
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S4 from The NOTCH4–HEY1 Pathway Induces Epithelial–Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma
Figure S4. Comparison of EMT-related genes between HEY1 high and low groups using TCGA data
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from The NOTCH4–HEY1 Pathway Induces Epithelial–Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma
Figure S4. Comparison of EMT-related genes between HEY1 high and low groups using TCGA data
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S5 from The NOTCH4–HEY1 Pathway Induces Epithelial–Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma
Figure S5. Comparison of HNSCC CSCs marker genes between NOTCH4, HEY1 high and low groups using the TCGA data set. ALDH1 expression in si-NOTCH4 and si-HEY1 cells.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from The NOTCH4–HEY1 Pathway Induces Epithelial–Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma
Figure S5. Comparison of HNSCC CSCs marker genes between NOTCH4, HEY1 high and low groups using the TCGA data set. ALDH1 expression in si-NOTCH4 and si-HEY1 cells.